Hawaii Biotech announced the award of a five year grant from the National Institute of Allergy and Infectious Diseases for the continued development of small molecule drugs to block the potentially lethal effects of Anthrax toxin. This award allows Hawaii Biotech to expand its product development efforts beyond vaccines to drug discovery and development. Hawaii Biotech is a HiBEAM portfolio company and Dr. Elliot Parks is the President and CEO. Click here for more information.